Subject: Agenda of the 94th meeting of the Pharmaceutical Committee

Venue: Due to emergency public health protection measures relating to the Covid-19 outbreak, the physical meeting is replaced by a teleconference.

Connection details to be sent to participants through AGM
1. Adoption of the draft agenda

2. Introduction by Commission

3. **Future proofing**: Adapting the legislative framework for medicinal products to support patient centred and need-driven innovation and scientific developments

   **Elements of discussion:**
   As indicated in the Commission Communication on the Pharmaceutical Strategy for Europe trends such as digitalisation, RWE, AI, personalised medicine, complex combination products, integrated therapies will influence innovation and scientific development.

   - What are the changes to make to the regulatory framework so that it is better adapted to support scientific developments and need driven innovation?
   - At which stage of the development are regulatory interventions necessary to support innovative product development? Which tools/instruments are necessary? (e.g. CMA, PRIME, Accelerated Assessment, Scientific Advice, rolling review, others?)

   **30 minutes COFFEE BREAK**

4. Providing **incentives for innovation that reaches the patient**

   **Elements of discussion:**
   - Would it be possible to set in the legislation criteria to identify products addressing unmet medical needs? What criteria can be considered?
   - How can the system of regulatory incentives (data and market protection; possible novel incentives) better address unmet needs? Are changes to the existing system needed and what would these be?
   - How can the regulatory framework better support a wider access to medicines?

5. A.O.B.

*** *** ***